Quick Answer
REVELATION BIOSCIENCES, INC. reported Operating Income Loss of -$9.07 million for the year ending 2025.
- REVELATION BIOSCIENCES, INC. showed a decrease of -13.7% in Operating Income Loss from 2024 to 2025.
- This data is from REVELATION BIOSCIENCES, INC.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: -$2.61 million | Q2 2021: -$2.44 million | Q3 2021: -$3.04 million | Q1 2022: -$6.59 million | Q2 2022: -$1.86 million | Q3 2022: -$1.20 million | Q1 2023: -$1.62 million | Q2 2023: -$1.93 million | Q3 2023: -$2.78 million | Q1 2024: -$1.90 million | Q2 2024: -$2.52 million | Q3 2024: -$1.80 million | Q1 2025: -$2.09 million | Q2 2025: -$2.46 million | Q3 2025: -$1.94 million.
- Over the full 5 years of available data (2021 to 2025), REVELATION BIOSCIENCES, INC.'s Operating Income Loss has grown by 24.1%.
- Historical annual values: Fiscal year 2025: -$9.07 million | Fiscal year 2024: -$7.98 million | Fiscal year 2023: -$8.66 million | Fiscal year 2022: -$10.86 million | Fiscal year 2021: -$11.95 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: